丁酸钠下调IRAK1改善肠易激综合征内脏高敏感
Sodium butyrate ameliorates visceral hypersensitivity by down-regulating IRAK1 in irritable bowel syndrome

DOI: 10.6040/j.issn.1671-7554.0.2018.186

Keywords: 丁酸钠,肠易激综合征,内脏高敏感,白介素-1受体相关激酶1,
Sodium butyrate,Visceral hypersensitivity,Irritable bowel syndrome,Interleukin-1 receptor-associated kinase 1

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders[J]. Gastroenterology, 2006, 130(5):1480-1491.
[2]	Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome[J]. Gastroenterology, 2004, 126(3):693-702.
[3]	Pozuelo M, Panda S, Santiago A, et al. Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome[J]. Sci Rep, 2015, 5:12693. doi:10.1038/srep12693.
[4]	Jain A, Kaczanowska S, Davila E. IL-1 receptor-associated kinase signaling and its role in inflammation, cancer progression, and therapy resistance[J]. Front Immunol, 2014, 5:553. doi:10.3389/fimmu.2014.00553.
[5]	Heiseke AF, Jeuk BH, Markota A, et al. IRAK1 drives intestinal inflammation by promoting the generation of effector the cells with optimal gut-homing capacity[J].J Immunol, 2015, 195(12):5787-5794.
[6]	Qi QQ, Chen FX, Zhao DY, et al. Colonic mucosal N-methyl-D-aspartate receptor mediated visceral hypersensitivity in a mouse model of irritable bowel syndrome[J]. J Dig Dis, 2016, 17(7):448-457.
[7]	Zhou Q, Yang L, Larson S, et al. Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1[J]. GUT, 2016, 65(5):797-805.
[8]	Liu Y, Xu Y, Ma H, et al. Hepatitis B virus X protein amplifies TGF-beta promotion on HCC motility through down-regulating PPM1a[J]. Oncotarget, 2016, 7(22):33125-33135.
[9]	Defrees DN, Bailey J. Irritable bowel syndrome: epidemiology, pathophysiology, diagnosis, and treatment[J]. Prim Care, 2017, 44(4):655-671.
[10]	Hungin AP, Paxman L, Koenig K, et al. Prevalence, symptom patterns and management of episodic diarrhea in the community:a population-based survey in 11 countries[J]. Aliment Pharmacol Ther, 2016, 43(5):586-595.
[11]	Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report[J]. GUT, 2013, 62(1): 159-176.
[12]	Moraru IG, Moraru AG, Dumitrascu DL. Irritable bowel syndrome and the small intestinal microflora. What do we know?[J]. Rom J Intern Med, 2015, 53(1):103-107.
[13]	Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease[J]. Neurogastroenterol Motil, 2012, 24(6):503-512.
[14]	Sinagra E, Pompei G, Tomasello G, et al. Inflammation in irritable bowel syndrome: Myth or new treatment target?[J]. World J Gastroenterol, 2016, 22(7):2242-2255.
[15]	Brown K, Abbott DW, Uwiera RRE, et al. Removal of the cecum affects intestinal fermentation, enteric bacterial community structure, and acute colitis in mice[J]. Gut Microbes, 2018, 9(3):218-235.
[16]	Zheng L, Kelly CJ, Battista KD, et al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2[J]. J Immunol, 2017, 199(8):2976-2984.
[17]	Zaleski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome[J]. Prz Gastroenterol, 2013, 8(6):350-353.
[18]	Elce A, Amato F, Zarrilli F, et al. Butyrate modulating effects on pro-inflammatory pathways in human intestinal epithelial cells[J]. Benef Microbes, 2017, 8(5):841-847.
[19]	Vollmer S, Strickson S, Zhang T, et al. The mechanism of activation of IRAK1 and IRAK4 by interleukin-1 and Toll-like receptor agonists[J]. Biochem J, 2017, 474(12):2027-2038.
[20]	Van den Abbeele P, Belzer C, Goossens M, et al. Butyrate-producing clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model[J]. ISME, 2013, 7(5):949-961.
[21]	Mishiro T, Kusunoki R, Otani A, et al. Butyric acid attenuates intestinal inflammation in murine DSS-induced colitis model via milk fat globule-EGF factor 8[J]. Lab Invest, 2013, 93(7):834-843.
[22]	Lehmann D, Radomski N, Lutke-Eversloh T. New insights into the butyric acid metabolism of Clostridium acetobutylicum[J]. Appl Microbiol Biotechnol, 2012, 96(5):1325-1339.
[23]	Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing(meta)genomic data[J]. MBio, 2014, 5(2):e889. doi:10.1128/mBio.00889-14.
[24]	Kumari R, Ahuja V, Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India[J]. World J Gastroenterol, 2013, 19(22):3404-3414.
[25]	Zhao Q, Chen G. Role of IL-33 and its receptor in T cell-mediated autoimmune diseases[J]. Biomed Res Int, 2014, 2014:587376. doi:10.1155/2014/587376.
[26]	Jin Z, Liang F, Yang J, et al. hnRNP I regulates neonatal immune adaptation and prevents colitis and colorectal cancer[J]. PLoS Genet, 2017,13(3):e1006672. doi:10.1371/journal.pgen.1006672.

Full-Text